english.prescrire.org > Prescrire International > N°141 - September 2013

n°141

September 2013

Issue Contents
Editorial

Free  Systematic, in-depth analysis

p.200
Because withholding the truth can adversely affect health

Marketing Authorisations


Intranasal live attenuated seasonal influenza vaccine (New Drug)

p.201-204
Does not challenge current practice

INN common stem: -oxetine

p.204

Oral fluconazole and vulvovaginal candidiasis (New Indication)

p.205
Prevention is not always better than cure

Free  Ferumoxytol (New Drug)

p.206
An intravenous iron, riskier than iron sucrose

Ciclesonide (New Drug)

p.207
Long-term treatment of persistent asthma: no clear progress

Adverse Effects


Drug-induced peripheral neuropathies

p.208-212
Mostly anti-cancer drugs

Drug-induced optic neuropathy in brief

p.210

Acitretin: no pregnancy during treatment and, as a precaution, for 3 years after discontinuation

p.213
Acitretin is a retinoid

Pramipexole: heart failure

p.213
Increased risk at treatment initiation

Reviews


Baclofen and severe alcohol dependence

p.214-217
An uncertain harm-benefit balance as of early 2013

Role of medications in the management of alcohol dependence

p.217

Secondary cardiovascular prevention: omega-3 fatty acids ineffective

p.218
A meta-analysis of comparative clinical trials

PSA home tests: ban in France is welcome

p.218
Unfavourable harm-benefit balance

Outlook


Bisphenol A: a body of evidence supporting exposure reduction

p.219-223
Precautionary measures are needed

Free  The French Sunshine Act

p.223
False transparency

Masthead


Free  Masthead

p.198

The complete contents of 
this issue of Prescrire International
are available for download by
Prescrire International subscribers.
Certain texts are also available to
non-subscribers for free download,
as indicated. 

 

Subscribe